TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Clinical trial NCT06206174 · RECRUITING

Trial details

NCT number: NCT06206174
Sponsor: Shenzhen TargetRx Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hematologic Malignancy Non Hodgkin Lymphoma Acute Myeloid Leukemia Acute Lymphoblastic Leukemia, Adult Myelodysplastic Syndromes

Start date: 2024-03-06
Primary completion: 2025-02-28
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.